{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:26:00Z","timestamp":1782912360372,"version":"3.54.5"},"reference-count":64,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Blast crisis (BC) is one of the most dreaded complications of chronic myeloid leukemia (CML). Fortunately, the incidence of BC has diminished markedly in the BCR-ABL tyrosine kinase inhibitor (TKI) era. The primary objective of initial treatment in BC is to achieve a second chronic phase (CP) and to proceed to an allogeneic stem cell transplantation (SCT) in eligible patients. The clinical outcome of patients with CML BC remains unsatisfactory, even with highly potent TKIs, as remissions are short lived and there is an unmet need for novel therapies. We provide a comprehensive summary reviewing the current management of Lymphoid BC.<\/jats:p>","DOI":"10.3390\/ijms231911836","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T23:39:31Z","timestamp":1665272371000},"page":"11836","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["B-Lymphoid Blast Phase\u2013Chronic Myeloid Leukemia: Current Therapeutics"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0207-329X","authenticated-orcid":false,"given":"Binoy","family":"Yohannan","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, The University of Texas Health Science Center at Houston, 6431 Fannin Street, Huston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binsah","family":"George","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, The University of Texas Health Science Center at Houston, 6431 Fannin Street, Huston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: Incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_5","first-page":"7276128","article-title":"A Rare Case of Chronic Myelogenous Leukemia Presenting as T-Cell Lymphoblastic Crisis","volume":"2018","author":"Padhi","year":"2018","journal-title":"Case Rep. Oncol. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.2147\/OTT.S251214","article-title":"Myeloid Blast Crisis of Chronic Myeloid Leukemia Followed by Lineage Switch to B-Lymphoblastic Leukemia: A Case Report","volume":"13","author":"Liu","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1046\/j.1365-2141.1998.00542.x","article-title":"\u2018Lymphoid\u2019 blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features","volume":"100","author":"Cervantes","year":"1998","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2017.36","article-title":"Differential signaling networks of Bcr\u2013Abl p210 and p190 kinases in leukemia cells defined by functional proteomics","volume":"31","author":"Reckel","year":"2017","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/cyto.b.21764","article-title":"Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia","volume":"96","author":"Raspadori","year":"2019","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000208322","article-title":"The Treatment of Terminal Metamorphosis of Chronic Granulocytic Leukaemia with Corticosteroids and Vincristine","volume":"50","author":"Marmont","year":"1973","journal-title":"Acta Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.1986.4.7.1079","article-title":"High-dose cytosine arabinoside: Treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis","volume":"4","author":"Iacoboni","year":"1986","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.1992.10.3.398","article-title":"Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor","volume":"10","author":"Kantarjian","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome\u2013positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome","volume":"344","author":"Zubay","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood.V99.10.3547","article-title":"Imatinib mesylate (STI571) therapy for Philadelphia chromosome\u2013positive chronic myelogenous leukemia in blast phase","volume":"99","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","article-title":"Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: Outcome of the patients alive after a 6-year follow-up","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/leu.2011.355","article-title":"Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase","volume":"26","author":"Giles","year":"2011","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3109\/10428194.2011.627480","article-title":"Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis","volume":"53","author":"Nicolini","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2006","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in Imatinib-Resistant Philadelphia Chromosome\u2013Positive Leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1002\/cncr.25123","article-title":"Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study","volume":"116","author":"Saglio","year":"2010","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A Phase 2 Trial of Ponatinib in Philadelphia Chromosome\u2013Positive Leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncr.28433","article-title":"HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia","volume":"120","author":"Strati","year":"2013","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.23624","article-title":"Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia","volume":"89","author":"Benjamini","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: Long-term follow-up of a single-centre, phase 2 study","volume":"5","author":"Jabbour","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/cncr.33539","article-title":"Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome\u2013positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib","volume":"127","author":"Morita","year":"2021","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/sj.leu.2404115","article-title":"High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia","volume":"20","author":"Rea","year":"2006","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome\u2013positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood-2018-99-120029","article-title":"A Phase II Study of Dasatinib and Dexamethasone as Primary Therapy Followed by Transplantation for Adults with Newly Diagnosed Ph\/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance\/CALGB Study 10701","volume":"132","author":"Wieduwilt","year":"2018","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: A single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1200\/JCO.2022.40.16_suppl.7011","article-title":"Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL)","volume":"40","author":"Macaron","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11912-022-01220-4","article-title":"Central Nervous System Involvement in Adults with Acute Leukemia: Diagnosis, Prevention, and Management","volume":"24","author":"Paul","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Paul, S., Kantarjian, H., Sasaki, K., Marx, K., Jain, N., Savoy, J.M., DiPippo, A., Jammal, N., Bravo, G.M., and Kadia, T. (2022). Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Am. J. Hematol.","DOI":"10.1002\/ajh.26622"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1200\/JCO.2020.38.15_suppl.7512","article-title":"Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R\/R PH+ ALL or CML in lymphoid blast phase (CML LBP)","volume":"38","author":"Jain","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1182\/blood-2018-99-114170","article-title":"Successful Salvage with Inotuzumab Ozogamicin in Relapsed\/Refractory Lymphoid Blast Crisis of Chronic Myeloid Leukemia after Failure of Multiple Lines of Therapy Including Blinatumomab","volume":"132","author":"Mansurov","year":"2018","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.clml.2017.08.101","article-title":"Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia","volume":"17","author":"Assi","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib\u2013Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"Bassan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2019-131838","article-title":"Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias","volume":"134","author":"McCloskey","year":"2019","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1200\/JCO.2021.39.15_suppl.7001","article-title":"Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study","volume":"39","author":"Short","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"E229","DOI":"10.1002\/ajh.26175","article-title":"An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"96","author":"Short","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Mauro","year":"2021","journal-title":"Blood"},{"key":"ref_44","first-page":"4470","article-title":"Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations","volume":"11","author":"Gleixner","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2020-142142","article-title":"Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1182\/blood-2019-127951","article-title":"PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I","volume":"134","author":"Turkina","year":"2019","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/bjh.12978","article-title":"SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia","volume":"166","author":"Frolova","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2013-07-517847","article-title":"The IL-2\/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells","volume":"123","author":"Kobayashi","year":"2014","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3109\/10428194.2013.812788","article-title":"Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-\u03b1 monotherapy","volume":"55","author":"Ilander","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Polivkova, V., Rohon, P., Klamova, H., Cerna, O., Divoka, M., \u010cu\u0159\u00edk, N., Zach, J., Novak, M., Marinov, I., and Soverini, S. (2016). Interferon-\u03b1 Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0155959"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41375-020-01011-5","article-title":"RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses","volume":"35","author":"Awad","year":"2020","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1182\/blood-2018-99-115768","article-title":"Allogeneic CAR-T Cell Therapy for Treatment of Relapse after Allo-HSCT in Patients with Refractory CML Lymphoid Blast Crisis: Significance of HLA Matched Donor\/Patient Pair in the Safety\/Efficacy of CAR-T Cell Therapy","volume":"132","author":"Sun","year":"2018","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1038\/s41375-020-0983-x","article-title":"Long: Molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy","volume":"34","author":"Venkataraman","year":"2020","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"10989","DOI":"10.2147\/OTT.S232102","article-title":"Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy","volume":"12","author":"Zhou","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","article-title":"Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML","volume":"129","author":"Warfvinge","year":"2017","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1158\/0008-5472.CAN-18-1078","article-title":"CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor\u2013Engineered T Cells","volume":"79","author":"Warda","year":"2019","journal-title":"Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Kim, N., Kim, M.-Y., Cho, Y.-U., Chen, W., Lee, K.-H., and Kim, H. (2020). PVR and ICAM-1 on Blast Crisis CML Stem and Progenitor Cells with TKI Resistance Confer Susceptibility to NK Cells. Cancers, 12.","DOI":"10.3390\/cancers12071923"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/bmt.2011.194","article-title":"Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: A CIBMTR analysis","volume":"47","author":"Khoury","year":"2011","journal-title":"Bone Marrow Transpl."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.bbmt.2019.06.028","article-title":"Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party","volume":"25","author":"Radujkovic","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/bloodadvances.2018024844","article-title":"Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia","volume":"2","author":"Chhabra","year":"2018","journal-title":"Blood Adv."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.1990.tb07832.x","article-title":"A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia","volume":"76","author":"Cervantes","year":"1990","journal-title":"Br. J. Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1182\/blood.V99.7.2304","article-title":"Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia","volume":"99","author":"Wadhwa","year":"2002","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11836\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:47:02Z","timestamp":1760143622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":64,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijms231911836"],"URL":"https:\/\/doi.org\/10.3390\/ijms231911836","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,5]]}}}